Interleukin-10 (IL-10) has been shown to be present at high levels in the ascites of ovarian cancer (OC) patients; however, little is known about its prognostic value. We sought to correlate IL-10 levels in ascites and sera of OC patients with clinicopathologic characteristics and oncologic outcomes. IL-10 levels and clinical data from biobanked ascites and serum samples of OC patients were evaluated. Receiver operating characteristic curves were used to quantify marker performance and identify IL-10-high and IL-10-low groups. Correlations between IL-10 levels and clinicopathologic data were performed. Survival outcomes were calculated, while the factors affecting them were also investigated. A total of 106 patients had ascites samples, of which 44 serum samples were also available. Mean ascites IL-10 levels were significantly higher in patients with serous histology compared to endometrioid histology (p= 0.024). Fold-change in ascites IL-10 during treatment positively correlated with clinical response, as determined by a change in serum cancer antigen (CA)-125 levels (p= 0.0126). Median progression-free survival (PFS) and overall survival (OS) were shorter in patients with high compared with low ascites IL-10 levels (PFS: 18 versus 60 months;p= 0.007, OS: 42 versus 85 months;p= 0.029). A significant positive correlation was seen between ascites and sera IL-10 levels (p= 0.019). In multivariable analyses, a high ascites IL-10 level was associated with a significantly worse prognosis (PFS hazard ratio (HR) = 1.93;p= 0.02). Patients with high ascites levels of IL-10 have worse outcomes, which are likely reflective of the immunosuppressive effect of IL-10. This highlights its potential role as an immunomodulator in the tumor microenvironment, leading to OC immune evasion.
白细胞介素-10（IL-10）在卵巢癌患者的腹水中呈现高表达，但其预后价值尚不明确。本研究旨在探讨卵巢癌患者腹水及血清中IL-10水平与临床病理特征及肿瘤学结局的相关性。通过分析生物样本库中卵巢癌患者的腹水与血清样本，评估其IL-10水平及临床数据。采用受试者工作特征曲线量化标志物效能，并据此划分IL-10高表达组与低表达组。分析IL-10水平与临床病理数据的相关性，计算生存结局并探究其影响因素。研究共纳入106例腹水样本患者，其中44例同时具备血清样本。浆液性组织学类型患者的腹水IL-10平均水平显著高于子宫内膜样组织学类型患者（p=0.024）。治疗期间腹水IL-10的倍数变化与血清癌抗原（CA）-125水平变化评估的临床疗效呈正相关（p=0.0126）。腹水IL-10高表达组患者的中位无进展生存期（18个月 vs 60个月，p=0.007）和总生存期（42个月 vs 85个月，p=0.029）均显著短于低表达组。腹水与血清IL-10水平呈显著正相关（p=0.019）。多变量分析显示，腹水IL-10高表达与不良预后显著相关（无进展生存期风险比=1.93，p=0.02）。腹水IL-10高表达的卵巢癌患者预后较差，这可能与IL-10的免疫抑制作用相关。本研究揭示了IL-10作为肿瘤微环境中免疫调节因子的潜在作用，其介导的免疫抑制效应可能导致卵巢癌发生免疫逃逸。
Ascites and Serum Interleukin-10 Levels as a Prognostic Tool for Ovarian Cancer Outcomes
肿瘤(癌症)患者之家